Saturday 17 October 2026
Export MREO’s income statement to Excel — free account
Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
0.30
0.01
−3.23%
Follow MREO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.09 | 9.53 | 5.86 | 5.31 | |
Current Ratio |
8.71 | 10.46 | 6.48 | 5.88 | |
Net Debt/EBITDA |
4.62 | 5.37 | 4.21 | 4.39 | |
Debt/Assets |
0.74% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.04 | 1.05 | 0.64 | 0.86 | |
Capex/Depreciation |
0.00 | 0.00 | (1.75) | 0.00 | |
Interest Coverage |
(368.39) | (351.78) | (438.30) | (439.37) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.05) | (0.03) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.05) | (0.03) | (0.04) | |
Cash per Share |
0.30 | 0.26 | 0.23 | 0.19 | |
Shareholders Equity per Share |
0.29 | 0.26 | 0.21 | 0.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.29 | 0.26 | 0.21 | 0.18 | |
Free Cash Flow |
(7.31) | (7.68) | (4.61) | (6.04) | |
Working Capital |
46.39 | 40.72 | 33.86 | 27.72 | |
Capital Expenditures |
0.00 | 0.00 | (0.30) | 0.00 | |
Net Current Asset Value |
45.40 | 40.02 | 33.47 | 27.34 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.31 | 1.89 | 3.08 | 1.13 | |
Average Assets |
71.17 | 61.15 | 54.47 | 48.67 | |
Average Common Equity |
59.57 | 50.94 | 47.07 | 41.41 |
Columns are period end dates